Dear Reader :

This month’s edition of Citeline’s newsletter, developed in alliance with the IPA, encapsulates advances in the development of off-the-shelf, CAR-T products and also partnering initiatives in the biosimilars segment.

The R&D head of Allogene Therapeutics talks about the firm’s pivotal trial in diffuse large B-cell lymphoma and also encouraging data in renal cell carcinoma, while in the biosimilars space Pfizer-Samsung and Alvotech-Advanz continue to build on their partnerships.

We also bring you some important data readouts from the recent ASCO meeting.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA


alt_text Perspective From Industry Leaders
In Quick Succession: Wave Of New Leaders Could Reshape Industry alt_text
In Quick Succession: Wave Of New Leaders Could Reshape Industry Exec Chat: Abbott’s Burton Talks About Abbott’s Plans To Address Chronic Pain With SCS

With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts ...
 

Allen Burton, the medical director of Abbott’s neuromodulation business and a leader in pain medicine, talked to Medtech Insight about the FDA’s ...
 
alt_text Licensing & Collaboration Agreements
alt_text alt_text
Alvotech Makes Multiple Moves As It Allies With Advanz For Five European Biosimilars Samsung Biologics Strikes $400m+ Biosimilars Supply Deal With Pfizer

In a busy week for Alvotech, the firm has announced an expansion of its partnership with Advanz to cover five further European biosimilars ...

Samsung Biologics and Pfizer have struck a “long-term” deal worth more than $400m that will see the Korean company manufacture multiple biosimilars....
alt_text Next Gen R&D
alt_text ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?
ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO ASCO 2023 – A Role For Immuno-Oncology In Ovarian Cancer At Last?

Servier’s targeted therapy, vorasidenib, can effectively delay the need for more drastic treatment in patients with low-grade glioma ...
 

AstraZeneca PLC appears to have teased out a positive result for Imfinzi in ovarian cancer – a setting that so far has proved intractable for anti-PD-(L)1 drugs. ...
alt_text Clinical Trials
alt_text alt_text
Allogene Advances Off-The-Shelf Mission With Pivotal Trial Progress, Solid Tumor Data UK Aims To Quadruple Patient Recruitment To Industry Clinical Trials By 2027

R&D head Zachary Roberts spoke with Scrip about Allogene’s Phase II pivotal trial for ALLO-501A and the firm’s hopes for overcoming challenges ... 

The UK government has set aside dedicated funds to deliver ambitious changes that would make it quicker and easier for companies to trial ...
Citeline Contact

Poornachandra Tejasvi .K, Senior Director - Emerging Markets, India

Mobile: +91 9945273146
Email: poornachandra.tejasvi@citeline.com
Client Services: clientservices@citeline.com
 
IPA Contact

Direct: +91 022 2610 9281
Email: info@ipa-india.org
alt_text alt_text alt_text